TITLE

Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine

AUTHOR(S)
Ciebiada, Maciej; Barylski, Marcin; Ciebiada, Malgorzata Gorska
PUB. DATE
March 2013
SOURCE
American Journal of Rhinology & Allergy;Mar/Apr2013, Vol. 27 Issue 2, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Because intercellular adhesion molecule (ICAM) 1 and recruitment of eosinophils are crucial in supporting allergic inflammation, their down-regulation may bring additional benefits in patients' recovery. We have assessed nasal eosinophilia and serum soluble ICAM-1 (sICAM-1) concentrations in relation to nasal symptoms in patients with persistent allergic rhinitis (AR) treated for 6 weeks with either desloratadine, levocetirizine, montelukast alone, or in combination. Methods: In this single-center, randomized, double-blind, placebo-controlled, crossover, two-arm study, 40 patients with persistent AR were randomized to receive either montelukast and/or levocetirizine or placebo (n = 20) or to receive treatment with montelukast and/or desloratadine or placebo (n = 20). Nasal eosinophilia and concentration of sICAM-1 in peripheral blood were assessed before and on the last day of each treatment period. Results: All active treatments in both arms of the study resulted in the decrease of sICAM-1 and nasal eosinophilia, which correlated with the severity of nasal symptoms. In the montelukast/levocetirizine arm, montelukast decreased nasal eosinophilia more significantly than levocetirizine, whereas in reduction of sICAM-1 all active treatment options were equally effective. However, in the desloratadine/montelukast arm, the resulting improvement of combination therapy of sICAM-1 and the influx of eosinophils was not statistically significant. Conclusion: The improvement of nasal symptoms in patients with AR treated with antihistamines, with or without montelukast, may additionally result from the reduction of sICAM-1 and nasal eosinophilia. Because the combination therapy may bring inconclusive benefits in this area there is a strong need of further studies to find mechanisms that favor combination therapy.
ACCESSION #
86447301

 

Related Articles

  • Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Vuurman, E. F. P. M.; Rikken, G. H.; Muntjewerff, N. D.; de Halleux, F.; Ramaekers, J. G. // European Journal of Clinical Pharmacology;Jul2004, Vol. 60 Issue 5, p307 

    Introduction. First-generation antihistamines taken for relief of allergic rhinitis are sedating and pose potential risks for those driving a car or operating machinery. Desloratadine is a potent, selective, histamine H1-receptor antagonist that does not easily cross the blood–brain...

  • Comparative Clinical Studies with Ebastine: Efficacy and Tolerability. Luria, X. // Drug Safety;Dec1999 Supplement, Vol. 21 Issue 6, p63 

    Ebastine is a nonsedating and selective histamine H receptor antagonist without anticholinergic or sedative effects at therapeutic doses. It has shown a rapid onset and long duration of action, and doses of 10 and 20mg once daily are effective in relieving the nasal and non-nasal symptoms of...

  • Antiinflammatory Effects of H1-Antihistamines: Clinical and Immunological Relevance. Vena, G. A.; Cassano, N.; Buquicchio, R.; Ventura, M. T. // Current Pharmaceutical Design;9/21/2008, Vol. 14 Issue 27, p2902 

    Signs supporting antiinflammatory effects of H1-antihistamines were first reported long ago, but their clinical relevance remains controversial, especially with respect to their ability to inhibit the release of histamine and other preformed mediators. Experimental studies have documented that...

  • Fexofenadine. Markham, A.; Wagstaff, A.J. // Drugs;Feb1998, Vol. 55 Issue 2, p269 

    â–´ The nonsedating histamine H receptor antagonist fexofenadine is the active metabolite of terfenadine. â–´ It reduced the allergic response in animal models of allergy and did not prolong the QT interval (QT) in dogs or rabbits at plasma concentrations many times higher than those...

  • Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Sherrill, J D; KC, K; Wu, D; Djukic, Z; Caldwell, J M; Stucke, E M; Kemme, K A; Costello, M S; Mingler, M K; Blanchard, C; Collins, M H; Abonia, J P; Putnam, P E; Dellon, E S; Orlando, R C; Hogan, S P; Rothenberg, M E // Mucosal Immunology (1933-0219);May2014, Vol. 7 Issue 3, p718 

    The desmosomal cadherin desmoglein-1 (DSG1) is an essential intercellular adhesion molecule that is altered in various human cutaneous disorders; however, its regulation and function in allergic disease remains unexplored. Herein, we demonstrate a specific reduction in DSG1 in esophageal...

  • A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Ellis, Anne K.; Yifei Zhu; Steacy, Lisa M.; Walker, Terry; Day, James H. // Allergy, Asthma & Clinical Immunology;2013, Vol. 9 Issue 1, p1 

    Background: Azelastine has been shown to be effective against seasonal allergic rhinitis (SAR). The Environmental Exposure Unit (EEU) is a validated model of experimental SAR. The objective of this double-blind, four-way crossover study was to evaluate the onset of action of azelastine nasal...

  • Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis. Ching-Yin Ho; Ching-Ting Tan // American Journal of Rhinology;Jul/Aug2007, Vol. 21 Issue 4, p439 

    Background: The aim of this study was to compare the effect of antileukotriene (anti-LT), antihistamine, and a combination of anti-LT and antihistamine on the symptoms and nasal resistance in allergic rhinitis patients. Methods: We performed a placebo-controlled study, with 120 persistent,...

  • Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Bernstein, Jonathan A.; Prenner, Bruce; Ferguson, Berrylin J.; Portnoy, Jay; Wheeler, William J.; Sacks, Harry J. // American Journal of Rhinology & Allergy;Sep2009, Vol. 23 Issue 5, p512 

    Background: Azelastine nasal spray is a topical antihistamine with a distinctive taste that may be objectionable to some patients. The primary objectives of this clinical trial were (1) to determine if a reformulated azelastine nasal spray (Astepro) with sucralose as a taste-masking agent...

  • Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. Yamamoto, Hideyuki; Yamada, Takechiyo; Sakashita, Masafumi; Kubo, Seita; Susuki, Dai; Tokunaga, Takahiro; Ogi, Kazuhiro; Terasawa, Yoko; Yamashita, Shinji; Kayano, Yuichiro; Masada, Mikio; Kimura, Yuichi; Fujieda, Shigeharu // Allergy & Asthma Proceedings;Mar/Apr2012, Vol. 33 Issue 2, p17 

    Cysteinyl leukotriene and leukotriene receptor occupancy have been linked to several processes in seasonal allergic rhinitis (SAR), including nasal congestion, rhinorrhea, and recruitment of inflammatory cells. We investigated whether add-on loratadine, an antihistamine, might be effective for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics